Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

S.Korean stocks rebound on tech boost, easing China property woes

10/19/2021 | 03:05am EST

* KOSPI rises, foreigners net buyers

* Korean won strengthens against U.S. dollar

* South Korea benchmark bond yield falls

* For the midday report, please click

SEOUL, Oct 19 (Reuters) - Round-up of South Korean financial markets:

** South Korean shares ended higher on Tuesday, boosted by tech heavyweights that tracked Nasdaq's gains and easing concerns over China's property sector. The won strengthened, while the benchmark bond yield fell.

** The benchmark KOSPI closed 22.36 points, or 0.74%, higher at 3,029.04, rebounding from a 0.28% fall on Monday and marking the fourth gain in five sessions.

** Chip giants Samsung Electronics and SK Hynix gained 0.57% and 0.62%, respectively, while platform companies Naver and Kakao added 2.77% and 4.94% each.

** Battery maker Samsung SDI also soared 3.12% after reports that the company agreed with global automaker Stellantis NV to jointly produce electric vehicle batteries for the North American market.

** Foreigners were net buyers of 146.4 billion won ($124.16 million) worth of shares on the main board.

** China Evergrande Group's main unit has remitted funds to pay an onshore bond coupon due on Tuesday, while a couple of other property firms made coupon payments this week, helping ease some concerns about the embattled and indebted sector.

** Capping the gains were rising oil prices that recouped earlier losses, as falling temperatures in China revived concerns about its ability to meet heating demand needs amid power and coal shortages.

** The won ended at 1,178.7 per dollar on the onshore settlement platform, 0.76% higher than its previous close.

** In offshore trading, the won was quoted at 1,178.4 per dollar, up 0.6% from the previous day, while in non-deliverable forward trading its one-month contract was quoted at 1,178.9.

** In money and debt markets, December futures on three-year treasury bonds rose 0.07 point to 108.62.

** The benchmark 10-year yield fell by 1.9 basis points to 2.380%. ($1 = 1,179.1700 won) (Reporting by Joori Roh; Editing by Rashmi Aich)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
KAKAO CORP. -1.99% 123000 End-of-day quote.57.89%
NAVER CORPORATION -0.77% 386500 End-of-day quote.32.14%
SAMSUNG BIOLOGICS CO.,LTD. 1.61% 884000 End-of-day quote.7.02%
SAMSUNG ELECTRONICS CO., LTD. 0.00% 72300 End-of-day quote.-10.74%
SK HYNIX INC. 0.43% 116000 End-of-day quote.-2.11%
STELLANTIS N.V. 0.01% 15.568 Delayed Quote.6.18%
11/29Samsung Biologics, GreenLight Biosciences Enter Deal to Produce COVID-19 mRNA Vaccines
11/29South Korean Stocks Fall for Fifth Session Over COVID-19 Variant Omicron Fears; Hyundai..
11/24GreenLight Biosciences and Samsung Biologics Announce Collaboration to Build Capacity f..
11/23South Korea’s Indexes Decline on Profit-Taking; Naver, LG Chem Decline over 2%
11/19South Korean Stocks Break Three-Day Losses to Close Higher; Samsung Biologics Jumps 6% ..
11/15Samsung Biologics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Mont..
11/15Samsung's Lee visits U.S ahead of likely $17 billion chip plant decision-media
11/15S.Korea stocks end 1% higher on chip, biopharma boost, U.S. data in focus
11/08South Korea Stocks Decline as Investors Eye US, China Inflation Data; Biopharma Stocks ..
11/08S.Korean stocks end at near 1-month low as biopharma shares slump
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Sales 2021 1 549 B 1,30 B 1,30 B
Net income 2021 439 B 0,37 B 0,37 B
Net Debt 2021 319 B 0,27 B 0,27 B
P/E ratio 2021 133x
Yield 2021 -
Capitalization 58 490 B 48 998 M 49 248 M
EV / Sales 2021 38,0x
EV / Sales 2022 33,1x
Nbr of Employees 2 886
Free-Float 25,0%
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | A207940 | KR7207940008 | MarketScreener
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts 0
Last Close Price 884 000,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Seok-Woo Jung Independent Director
Sector and Competitors